Baxalta, the biopharmaceutical company recently spun out from Baxter, has signed a research collaboration with Novimmune SA, a Geneva, Switzerland-based biopharmaceutical company to develop novel bispecific antibodies for an unspecified indication. Financial terms of the deal were not disclosed.

Bispecific antibodies used in biopharmaceutical applications have been constructed using chemical linkers, non-human material, antibody fragments, or other forms of engineering. Novimmune says its kappa-lambda antibodies are allowed to assemble naturally, which offer potential development and safety characteristics such as a longer half-life, increased stability, and a lower risk of provoking an unwanted reaction in patients.

Source: Novimmune